Oppenheimer Maintains Outperform on Bicycle Therapeutics, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Bicycle Therapeutics (NASDAQ:BCYC) with a $48 price target.
August 07, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Bicycle Therapeutics with a $48 price target.
The reaffirmation of an Outperform rating and a $48 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100